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Abstract 
Breast cancer is a leading cause of death in women in the United States, with hereditary 
breast cancers accounting for approximately 10% of the diagnoses.  Nevertheless, women 
can decrease their risk by obtaining genetic testing and are often referred for the test if 
one or more of their relatives has been diagnosed with breast cancer and has the 
BRCA/BRCA2 cancer mutation.  The purpose of the current study was to examine 
predictors of healthy women’s (ages 18 to 35) hypothetical decisions about genetic 
testing and prophylactic treatments for the BRCA1/BRCA2 genetic mutations by 
measuring social problem solving (SPS) variables, health anxiety, and psychological 
distress.  A survey format to was used to determine whether there was a relationship 
between these variables, genetic testing, and/or prophylactic treatment decisions.  
Measures included the Social Problem-Solving Inventory-Revised, Short Form (SPSI-
R:S), Health Anxiety Inventory (HAI), Brief Symptom Inventory (BSI), a demographic 
questionnaire, and two hypothetical vignettes.  Results revealed that positive problem-
solving orientation (PPO) is predictive of prophylactic treatment decisions.  The results 
support the literature in that genetic testing decisions are difficult to predict, and other 
factors that have yet to be determined may be contributing to the decision.  Future 
research should look at these relationships in larger non-hypothetical samples and in 
different disease groups to determine whether the results differ. 
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Chapter 1: Introduction 
Statement of the Problem 
Second to skin cancer, breast cancer is the most commonly diagnosed cancer in 
the United States (accounting for one in three cancers) and, after lung cancer, it is a 
leading cause of cancer-related cause of death in women (DeSantis, Ma, Bryan & Jemal, 
2014).  In families with no history of breast cancer, the risk of developing breast cancer 
by age 30 is 4.07% and by age 50, the risk more than doubles to 8.76% (Bleyer & Welch, 
2012).  Moreover, as of 2016, it was estimated that there were more than 3.5 million 
women with a history of invasive breast cancer living in the United States (Miller et al., 
2016).  Compared to other cancers, breast cancer is typically diagnosed at younger ages 
(breast cancer median age = 61; lung cancer median age = 70; colorectal cancer median 
age = 68). 
Although the incidence of breast cancer remains fairly low in the general 
population, hereditary breast and ovarian cancers (HBOC)—breast and ovarian cancers 
with a hereditary basis—occur in approximately 10% of the population (Daly et al. 2010; 
Howlader et al., 2012).   HBOC are most commonly caused by mutations, also known as 
deleterious variances, in the BRCA1 and BRCA2 genes (D. M Eccles et al., 2015).  
Although the BRCA1/BRCA2 genes are implicated in the development of breast cancer, 
they only account for 20% of hereditary breast cancers, as a number of other hereditary 
cancer susceptibility genes have been identified (Antoniou et al., 2003; Crawford et al., 
2017; D. M. Eccles et al., 2015).  
Due to the high heritability of the BRCA1/BRCA2 mutations, first degree 
relatives (FDRs; those who have had a parent and/or sibling diagnosed with breast 
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cancer) are often referred for genetic testing services (Crawford et al., 2017).  For 
instance, genetic testing is encouraged if the FDR meets certain criteria, including but not 
limited to a history of breast cancer prior to the age of 50 in one or more first-degree 
relative(s), a family member with a known BRCA1/BRCA2 mutation, a family history of 
breast cancer in one or more first-degree relatives (particularly if they are diagnosed at 
younger ages), and a family member with the BRCA1/BRCA2 genetic mutation (Daly et 
al., 2010; Wevers et al., 2011).  Genetic testing can reduce risk, but it can also be 
uncertain and anxiety provoking.  Given that genetic testing is inherently ambiguous, for 
some people it can have negative psychological consequences (i.e., psychological distress 
or health anxiety; Butow, Lobb, Meiser, Barratt, & Tucker, 2003).  For example, the 
amount of uncertainty that one has about genetic testing has been found to be related to 
psychological distress (Frost, Venne, Cunningham & Gerritsen-McKane, 2004).  
Although uncertainty is a natural consequence of genetic testing, high degrees of 
uncertainty are considered to be related to knowledge of individual risk versus perceived 
risk, communication with genetic counselors (i.e., feeling fully informed), and uncertain 
genetic testing results (Croyle, Smith, Botkin, Baty, & Nash, 1997; Frost et al., 2004).  
Nevertheless, even with high levels of uncertainty, premorbid levels of psychological 
distress have been found to be strong predictors of the degree of distress experienced 
post-testing (Reichelt, Heimdal, Møller, & Dahl, 2004).  
Health anxiety is the anxiety that is brought on, maintained, and exacerbated by 
health-related stimuli and can be an understandable effect as people move through the 
genetic testing and prophylactic treatment process (Starcevic, 2013).  Health anxiety can 
arise or become exacerbated at any time, such as before testing or treatment or while 
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waiting for the results or surgery, and even if the results are negative, health anxiety can 
remain after the results have been received or after the surgery has happened.  To 
illustrate, Rimes and Salkovskis (2002) identified four factors that are thought to be 
fundamental to the perception of threat and the subsequent experience of genetic testing 
related health anxiety: (a) perceived likelihood that the illness will develop, (b) perceived 
severity of illness course, (c) perceived ability cope with the illness, and (d) level of 
support that will be available if the illness were to develop.  In addition, self-esteem and 
self-efficacy are considered to moderate the amount of health anxiety that is experienced 
(Audrain et al., 1997).  
The process of making genetic testing and prophylactic treatment decisions is 
complicated, as it requires people to make fairly quick life-altering decisions.  Social 
problem-solving (SPS) can assist in this endeavor and is defined as the problem-solving 
skills that people use in their natural environments (D’Zurilla & A. M. Nezu, 1982).  SPS 
is helpful in stressful situations and has been found to be predictive of overall adjustment 
and emotional well-being (Chang, D’Zurilla, & Sanna, 2004; D’Zurilla & A. M. Nezu, 
1982; Dreer et al., 2009).  For example, Dreer et al. (2009) conducted correlational 
research demonstrating that positive problem-solving abilities (i.e., identifying the 
problem, weighing pros and cons of solutions) relate to a decrease in depression in those 
with chronic diseases and their caregivers.  
Not surprisingly, positive problem-solving yields positive health outcomes, 
including a more positive perception of overall health, engagement in healthy lifestyle 
behaviors (i.e., exercise), and adherence to medical recommendations (Dreer, Elliott & 
Tucker, 2004; Elliott & Shewchuk, 2003).  In fact, when SPS skills are taught to breast 
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cancer patients and relatives undergoing genetic testing, adaptive coping increases 
(McClure, A. M. Nezu, C. M. Nezu, O’Hea, & McMahon, 2012).  In sum, strong 
problem-solving skills appear to be associated with multiple positive health-related 
outcomes and, when applied effectively, may protect against psychological distress and 
health anxiety. 
Purpose of the Study 
The purpose of this study was to examine the factors that may predict FDR’s 
BRCA1/BRCA2 genetic testing and prophylactic decisions by providing hypothetical 
vignettes to a sample healthy of women between the ages of 18 and 35.  The current 
study evaluated whether SPS variables (i.e., problem-solving orientation, rational 
problem solving, avoidance style, and impulsivity/carelessness style), psychological 
distress, and health anxiety predict a healthy FDR’s hypothetical choice to have genetic 
testing.  Information gained from this study may provide further insight into the genetic 
testing and prophylactic treatment decision making process.   
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Chapter 2: Literature Review 
Breast cancer is the most commonly diagnosed invasive cancer in women in 
North America and the second leading cause of cancer death in the United States (Ban & 
Godellas, 2014).  In 2017, there was an estimated 252,710 new breast cancer diagnoses 
(15% of all cancer diagnoses) and approximately 40,610 breast cancer related deaths 
(6.8% of all cancer deaths; Surveillance, Epidemiology, and End Results Program 
[SEER], 2017).  Nevertheless, advances in medicine (i.e., adjuvant therapy) and medical 
technology (i.e., screening advances) have led to earlier breast cancer detection and 
decreased mortality rates (1975i: 105.1 new cases, 31.4 new deaths; 2014iii: 125.3 new 
cases, 20.5 new deathsiv; Plevritis et al., 2018; SEER, 2017). 
Genetic Basis of Breast Cancer 
When working correctly, BRCA1/BRCA2 tumor suppressor proteins play an 
important role in repairing damaged deoxyribonucleic acid (DNA; Majdak-Paredes & 
Fatah, 2009).  These proteins are integral in securing each cell’s genetic material and, 
therefore, stopping abnormal cell growth (Majdak-Paredes & Fatah, 2009).  As a result of 
their function, mutations in either protein can lead to tumor growth.  The 
BRCA1/BRCA2 mutations are inherited from either parent (autosomal dominant) and 
occur equally in men and women; however, women are disproportionately affected 
(Hamilton, Lobel, & Moyer, 2009; Struewing et al., 1997).  These mutations exhibit 
incomplete penetrance (i.e., not everyone who inherits the gene will develop cancer; 
Parmigiani, Berry, & Aguilar, 1998).  The relationship between the mutation and cancer 
risk is determined not only by genetic factors but by environmental factors as well 
(Hamilton et al., 2009). 
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When a BRCA1/BRCA2 mutation is inherited, it is classified as BRCA1/BRCA2-
associated HBOC (Petrucelli, Daly, & Pal, 2016).  In women, BRCA1/BRCA2-
associated HBOC increases risk for breast and ovarian cancers, pancreatic cancer, and 
melanoma (cutaneous and ocular; Petrucelli et al., 2016).  Although not entirely within 
the scope of this paper, there are additional hereditary breast cancer syndromes that are 
caused by mutations in other proteins (Thull & Vogel, 2004).  Additional hereditary 
breast cancer syndromes include site-specific breast cancer (which may be associated 
with mutations in the BRCA1/BRCA2 genes), Cowden syndrome (CS) or multiple 
hamartoma syndrome, LieFraumeni syndrome (LFS), Peutz-Jegher syndrome (PJS), 
ataxia-telangiectasia (AT) syndrome, and low-penetrance breast cancer allele 
CHEK2*1100delC (Thull & Vogel, 2004).  The risk for HBOC cancers are dependent on 
which mutation occurs (BRCA1 or BRCA2; Petrucelli et al., 2016).  
BRCA1/BRCA2 Risk Factors 
Having a comprehensive knowledge of the risk factors for the BRCA1/BRCA2 
mutation is the first step in making informed prophylactic treatment decisions (i.e., 
mastectomy and oophorectomy).  Recent literature suggests that awareness of risk prior 
to genetic testing can predict levels of psychological distress post-testing (higher risk 
increases psychological distress; Cicero et al., 2017; Himes et al., 2016).  Yet, even with 
this knowledge, the risk factors are complex and uncertainty persists pre- and post-
testing.  Genetic testing is typically recommended in patients who have personal and/or 
family histories (first, second, or third degree relative) and any of the following 
characteristics: (a) two or more family members diagnosed with breast cancer, with at 
least one diagnosed at less than 50 years of age; (b) three or more family members 
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diagnosed with breast cancer at any age; (c) family history of male breast cancer; (d) a 
breast cancer diagnosis prior to age 51; I past or current diagnosis of ovarian cancer; (f) 
history of multiple primary breast cancers in one or both breasts; (f) personal or family 
history of triple-negative (estrogen receptor-negative, progesterone receptor-negative, 
and human epidermal growth factor receptor [HER2/neu] 2-negative) breast cancer, 
particularly when diagnosed before age 60 years; (g) a relative with the BRCA1/BRCA2 
mutation (Kim, Puymon, Qin, Guru, & Mohler, 2013). 
In HBOC families at high risk for the BRCA1/BRCA2 mutation, age is an 
important factor.  The U.S. Preventive Services Task Force (USPSTF) reviewed the 
literature and provided recommendations for risk assessment, genetic counseling, and 
genetic testing for the BRCA1/BRCA1 mutations for asymptomatic women with a family 
history of breast or ovarian cancer (Moyer, 2014).  The USPSTF recommends women 
from high risk families undergo genetic testing at age 18, even though the risk of 
developing breast cancer in the 18 to 24 age range is only approximately 1% (Moyer, 
2014; Patenaude et al., 2013).  
Despite low risk in some women who test positive, decreasing the risk of breast 
cancer begins early and continues throughout the lifespan.  The National Comprehensive 
Cancer Network (NCCN; 2018) outlined the following guidelines for BRCA mutation-
positive women: (a) women between the ages of 18 and 24 should begin monthly breast 
self-exams (BSE) at the end of menses, (b) at age 25, BRCA1/BRCA2 positive mutation 
carriers are highly advised to begin receiving clinical breast exams from their 
obstetrician-gynecologist (OB-GYN) every 6 to 12 months and getting annual breast 
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MRIs with contrast, and (c) from age 30 to 75, women are strongly encouraged to 
continue to receive their annual breast MRIs along with annual mammographies.  
In addition to age, environmental factors can increase the risk of developing 
breast cancer in mutation carriers (Friebel, Domchek, & Rebbeck, 2014).  In a meta-
analysis completed by Friebel et al. (2014), 44 studies were reviewed to assess for 
potential BRCA1/BRCA2 protein risk modifiers.  Certain reproductive factors and 
environmental exposures were found to influence breast cancer risk separately in each 
gene, specifically oral contraceptive use, smoking (greater than 4 years), nulliparity, and 
earlier age at menarche (Table 1; Friebel et al., 2014).  
 
 
 
Table 1 
Risk Modifiers in BRCA1/BRCA2 Mutation Carriers 
 BRCA1 BRCA2  
Reproductive   Nulliparity versus Parity: 
Each live birth decreases 
risk 
 
 Breastfeeding: Reduced 
risk if breastfeeding 
occurred for longer than 
one year 
 
 
 
 Age at Menarche: 
Reduced risk with later 
age 
 
 
 Nulliparity versus Parity: 
More than three live 
births decreases risk 
 Breastfeeding: Null 
results reported 
 
 Age at Menarche: Null 
results reported 
Exposures  Oral contraceptive use: 
Increased risk  
 
 Smoking: Possible risk. 
Results inconsistent. 
 
 Oral contraceptive use: 
Increased risk 
 
 Smoking: Increased risk 
 
 
Note. Data for risk modifiers in BRCA1/BRCA2 mutation carriers from Friebel et al. (2014) 
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Race and Ethnicity 
Even with advancements in medical treatment and technology, there continues to 
be racial and ethnic differences in diagnosis, survival, and treatment access (Iqbal, 
Ginsburg, Rochon, Sun, & Narod, 2015).  This has been found to be especially true in 
African American women, about whom there has been research to support differences 
between the biology of their tumors and those of other races/ethnicities (Iqbal et al., 
2015).  For example, Newman et al. (2006) identified 20 studies in which survival rates 
were reported and found that, even after adjusting for socioeconomic status (SES), 
African American ethnicity was an independent and significant predictor of poorer 
survival from breast cancer.  In regard to treatment access, McCarthy et al. (2016) 
reported differences in recommendations for BRCA1/BRCA2 testing between white and 
black women, where black women are less likely to receive a recommendation for 
genetic testing from an oncologist or surgeon. While the reasons were unclear the authors 
suggested the physician’s concerns about costs and lack of insurance coverage and the 
possibility of an incomplete family history (McCarthy et al., 2016; Murff, Byrne, Haas, 
Puopolo, & Brennan, 2005).  Samson et al. (2016) also showed that despite being 
screened for breast cancer, Black women are at a higher risk of being diagnosed in later 
stages and having a poorer chance for survival.  Low adherence, which can be accounted 
for by socioeconomic factors, may contribute to these findings (e.g.,, lack of insurance 
leading to nonadherence to treatment recommendations; Adams et al., 2009).   
Women minorities are also often suspicious of their medical providers, 
subsequently increasing the chance for low adherence and poor treatment outcomes 
(Table 2; Matthews, Sellergren, Manfredi, & Williams, 2002).  To combat the patient’s 
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uneasiness, evidence suggests that medical providers should pay close attention to their 
own biases, as they can impact patients’ communication styles and self-concepts (Ashton 
et al., 2003).  Additional recommendations include providing adequate time and 
appropriate prompts to allow the patient ask questions and express concerns (Ashton et 
al., 2003). 
 
 
Table 2 
Age-Adjusted Rates of Diagnosis and Survival by Race in Breast Cancer 
  
Age-adjusted  
diagnosis rates 
(per 100,000) 
 
 
Survival rates  
(crude 10-year) 
 
Non-hispanic white  129 80% 
Black 123 66% 
Hispanic American 94 82% 
Asian  93 78% 
Note. Data for rates of diagnosis and percentage of survival from Howlader et al. (2012) 
 
 
Genetic Testing 
Genetic testing is a type of medical test that identifies mutations in DNA proteins 
(Calzone & Biesecker, 2002).  Genetic tests are routinely performed prenatally to assess 
for chromosome abnormalities in the fetus (Calzone & Biesecker, 2002).  Outside of 
prenatal care, genetic testing is now being used to assess for risk for various diseases 
(Calzone & Biesecker, 2002).  The three types of genetic testing that are available are 
carrier, pre-symptomatic, and predisposition.  Carrier testing is typically done to look at 
reduced enzyme activity in recessive gene mutations, as reduced enzyme activity can be 
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indicative of specific types of gene mutations (e.g., cystic fibrosis; Mansoura & Collins, 
1998).  In conditions such as Alzheimer’s disease, pre-symptomatic testing determines 
with certainty if the disease will develop.  Finally, predisposition testing is used in 
healthy people to determine their risk of developing a disease (e.g., BRCA1/BRCA2 
mutation; Mansoura & Collins, 1998).  
Predisposition testing is linked to an increase in distress and anxiety because of 
the chance for uncertain outcomes, as testing results can be positive or negative, and 
include variants of uncertain significance (VUS) falling between 0.05 and 0.949 
probability of pathogenesis (B. K. Eccles, Copson, Maishman, Abraham, & D. M. Eccles, 
2015; Lumish et al., 2017).  Moreover, the incidence of VUS differs based on race and 
ethnicity (African Americans = 21%; European Americans = 5% to 6%; Lindor, Goldgar, 
Tavtigian, Plon, & Couch, 2013).  Lumish and colleagues (2017) surveyed 232 patients 
with HBOC who had previously undergone pre-symptomatic genetic testing and found 
that those who reported increased distress had no prior history of cancer and had received 
a VUS.  Conversely, patients who have received pre-symptomatic genetic testing for 
Huntington’s disease (HD) trend toward less distress post-testing, but this result is 
contingent on whether one is a mutation carrier and the disease in question, as being a 
mutation carrier in HD means that there is a 100% chance that the disease will develop 
(Crozier, Robertson, & Dale, 2015).  
 Genetic testing uptake rates vary and are determined by a myriad of factors, 
including personal and/or family history of breast cancer.  For instance, among FDRs, the 
possibility that a positive test could mean the need for prophylactic treatment can 
complicate matters further and increase the risk for the onset of psychological distress 
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(Metcalfe et al., 2010; Schwartz et al., 2002).  Another factor contributing to the 
complexity of genetic testing and prophylactic decisions is that genetic testing uptake 
rates vary; research has yet to determine exactly what causes this variability.  It is clear 
that personal and/or family history of breast cancer impacts decisions, but the type of 
research design (e.g., hypothetical vs real) appears to have an impact on the amount of 
genetic testing uptake that is reported (Ropka, Wenzel, Phillips, Siadaty & Philbrick, 
2006).  For example, Ropka et al. (2006) systematically reviewed 40 studies and 
determined that the mean genetic testing uptake in BRCA1/BRCA2 FDRs was 66% 
(range = 20% to 96%) in hypothetical studies and 59% (range = 25% to 96%) in real 
scenarios.  To summarize, the large amount of variance in genetic testing and 
prophylactic treatment uptake rates are most likely due to study methodology as well as 
the variety of personal and environmental factors that contribute to the decision.  
Genetic Testing and Psychological Variables 
 Psychological distress.  As genetic testing has been on the rise, so has the 
discussion about the role that psychological variables play in the process.  Psychological 
distress is defined as a persistent worry, anxiety, and decreased mental health in response 
to a stressful life event (Audrain et al., 1997).  Baum, Friedman, and Zakowski (1997) 
proposed a model, based on Lazarus and Folkman’s (1984) theory of stress and coping to 
explain the relationship between stress and genetic testing.  The authors proposed that 
individuals at risk for genetically inherited diseases that received positive results and 
were also low in coping skills, support, and/or psychosocial resources would have higher 
stress levels (Baum, Friedman, & Zakowski, 1997). 
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 Similarly, Hamilton and Bowers (2007) developed a theory of genetic 
vulnerability where they outlined six concepts that contribute to one’s distress pre and 
post-testing: (a) experiencing cancer within the family, (b) testing for a mutation, (c) 
understanding disease risk, (d) foregrounding the disease, (e) responding to knowledge of 
genetic vulnerability, and (f) altering or avoiding the family history of disease.  
In addition, a prior occurrence of cancer in the family can influence how one copes 
throughout the genetic testing and prophylactic process (Hamilton & Bowers, 2007). 
 In other words, the authors found that a past history of cancer in the family can 
impact perceived risk, the amount of distress that is felt in respect to telling one’s family 
about the test result (i.e., foregrounding: bringing the disease to the forefront), the ability 
to cope with the results of the genetic test, and how one incorporates the information into 
one’s prior experiences with the disease (Hamilton & Bowers, 2007).  Ultimately, the 
decision-making process is highly influenced by past experiences, especially if the cancer 
occurred within the immediate family system (Hamilton & Bowers, 2007).  
Although not applied formally, the themes of Baum et al. (1997) and Hamilton 
and Bowers (2007) are seen throughout the BRCA1/BRCA2 genetic testing literature.  
For example, Fletcher et al. (2006) determined factors associated with psychological 
distress in first-degree female relatives (N = 624) of newly diagnosed cancer patients.  
Fletcher and colleagues found that greater optimism was associated with low cancer-
related and general distress; however, avoidance of disease-related stimuli and a close 
relationship with the cancer patient resulted in higher levels of cancer-specific distress 
and low levels of general distress (Fletcher et al., 2006).  
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Ringwald et al. (2016) reviewed 1,243 studies that included measures of 
psychological distress, anxiety, and depression among cancer-affected BRCA1/BRCA2 
mutation carriers post-genetic testing.  The results of this review were contradictory.  In 
general, a positive test result increased depression, distress, and anxiety for 12 months 
post-testing (Ringwald et al., 2016); however, the authors also identified multiple studies 
which found the opposite, in which both cancer-affected and non-affected mutation 
carriers did not display increased levels of depression or anxiety (e.g., Claes et al. 2004; 
Schwartz et al. 2002).  
Smith et al. (2008) also assessed psychological distress and quality of life in those 
with a family and personal history of breast cancer.  Interestingly, findings indicated that 
women who declined to be tested reported a higher incidence of distress compared to 
women who received negative or uncertain results.  Consistent with previous literature, 
women who received a positive result experienced heightened distress for a short period 
of time (approximately three months), with distress levels returning to baseline a few 
months after the results were received (Smith et al., 2008).  
In general, it is clear that there is significant variability with regard to the way 
people respond to and are affected by genetic testing decisions.  The inconsistency in the 
psychological distress literature could be attributed to individual variation in decision 
making and problem-solving processes, availability of pre-testing genetic counseling 
services, levels of general psychological distress pre-testing, demographic variables, past 
history of cancer, and past psychiatric history (e.g., premorbid depression and anxiety; 
Catania et al., 2016; Reichelt, Møller, Heimdal, & Dahl, 2008; Ringwald et al., 2016).  
Overall, the research demonstrates several themes: (a) genetic testing can prove 
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psychologically beneficial for many individuals, (b) not knowing results of genetic 
testing tends to have a negative impact on distress levels, and (c) perceived risk (i.e., the 
amount of risk a person thinks he or she has of developing the disease) seems to be 
heightened in women who decline genetic testing.  Given the inconsistent findings, more 
research is needed understand fully how genetic testing decisions are made and the 
psychological impact that occurs both pre- and post-testing and in regard to prophylactic 
treatment. 
 Health anxiety.  Health anxiety—which has a lifetime prevalence of 
approximately 5% and is now classified as illness anxiety disorder in the fifth edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)—is persistent 
anxiety about health that includes little to no somatic complaint (American Psychiatric 
Association, 2013; Starcevic, 2013; Tyrer et al., 2014).  Typically, within medical illness, 
a cognitive-behavioral (CB) model of health anxiety is applied.  The CB model of health 
anxiety is based on Lazarus and Folkman’s (1984) theory, which states that, in the 
absence of psychological arousal, how life events are appraised depends on whether the 
situation is deemed “good” or “bad,” as well as the perceived causes of the event.  
Therefore, a situation that is appraised as a threat will be placed in a negative category 
and cause feelings of fear and anxiety (Lazarus & Folkman, 1984).  Comparatively, the 
CB model suggests that those at risk for health anxiety interpret medical information 
negatively (i.e., as a threat) and that the appraisals are influenced by preexisting health 
beliefs, beliefs about the disease (i.e., belief that breast cancer will lead to role changes 
and, ultimately, death), and the amount of anxiety that occurs after the appraisal has been 
made (Warwick & Salkovskis, 1990).   
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Within the CB model of health anxiety, there are fundamental cognitions that lead 
to the development or maintenance of the disorder that include perceived risk both for 
illness diagnosis and severity, perceived ability to cope with the diagnosis, and perceived 
effectiveness of available treatments (e.g., chemotherapy; Salkovskis & Warwick, 2001; 
Warwick, 1989).  The research on health anxiety, breast cancer, and genetic testing is 
limited, with the majority of the research measuring generalized anxiety, state/trait 
anxiety, or general distress.  Nonetheless, Rimes et al. (2006) assessed patients’v (N = 
218) responses to genetic counseling using the CB model of health anxiety.  The results 
were consistent with the CB model, as study participants’ preexisting health anxiety and 
interpretations predicted levels of health anxiety and distress post-counseling (Rimes, 
Salkovskis, Jones, & Lucassen, 2006).  Interestingly, compared to those with a family 
history of colon cancer, FDRs of breast and ovarian cancer patients were significantly 
more anxious post-counseling (Rimes et al., 2006).  
Perceived risk of having a positive genetic test is another important factor when 
determining the rate of health anxiety that a person may experience.  Research has shown 
that prior to genetic testing, patients tend to overestimate their risk, but the majority of 
the time, anxiety returns to baseline, especially if a patient feels that he or she has a 
competent medical team (Burke et al., 2000; Cicero et al., 2017; Katapodi, Facione, 
Humphreys, & Dodd, 2005; Sanders, Campbell, Sharp, & Donovan, 2003).  
Nevertheless, Sanders et al. (2003) found that perceived risk and subsequent distress were 
dependent on whether the individual had experienced the death of a relative from the 
disease, because it brought about thoughts of his or her own mortality.  
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In addition, factors have been found to account for higher levels of both health 
and generalized anxiety, including older age (younger women are more agreeable to 
being in a surveillance program and less likely to experience health anxiety when they do 
not undergo genetic testing), having children, a high level of uncertainty, a current 
diagnosis of cancer, being unmarried, receiving a lower level of education, having a 
lower level of optimism, and endorsing feelings of not being in control (Audrain et al., 
1997; Lodder et al., 2003). 
In sum, premorbid health anxiety, preexisting interpretations about health, and 
experiences with cancer in the family can all impact the amount of health anxiety that 
occurs both before and after genetic testing.  Health anxiety can increase the risk for 
maladaptive behaviors (i.e., avoidance); however, genetic counseling can decrease health 
anxiety if the following occurs: (a) the genetic counselor is aware of the individual’s past 
medical, family, psychological, and emotional history and (b) the genetic counselor 
provides enough information and education that a patient believes that he or she 
understands his or her level of genetic risk (Meiser & Halliday, 2002).  
 Social problem-solving.  Social problem-solving (SPS) is defined as how people 
solve problems in their natural environments (D’Zurilla & A. M. Nezu, 1982, 1999).  In 
other words, SPS is the CB process that facilitates one’s own coping mechanisms 
(adaptive or maladaptive) when faced with problems in everyday life (D’Zurilla & A. M. 
Nezu, 1982, 1999).  SPS consists of two processes: (a) problem-solving orientation (i.e., 
the motivational component: a negative or positive schema that influences whether a 
person believes that everyday problems can be solved), and (b) problem-solving styles 
(i.e., the person’s set of problem-solving skills: the cognitive and behavioral process that 
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an individual uses to determine which coping mechanisms he or she should apply to the 
problematic situation; A. M. Nezu, C. M. Nezu, & Perri, 1989).  
The way in which a problem is approached and solved is based primarily on how 
problems were solved in the past and how those situations shaped how a person thinks 
and feels about his or her ability to solve problems effectively (D’Zurilla & A. M. Nezu, 
1990).  Research demonstrates the effectiveness of problem-solving training (SPS applied 
in a treatment protocol) in a wide variety of settings and diagnoses (e.g., breast cancer 
patients and increasing adherence in diabetes management; Hill-Briggs et al., 2011; 
Hopko et al., 2011). Thus, it is not surprising that recent research has shown adaptive 
SPS skills to be a protective factor against the psychological distress that may occur as a 
result of cancer (Hopko et al., 2011).  To illustrate, when an individual applies adaptive 
problem-solving processes, he or she does not see the problem as one that cannot be 
solved and, thus, engages a series of skills (e.g., running through a list of possible of 
solutions and their alternatives) that decrease the chance that he or she will be unhappy 
with the outcome (Chang et al., 2004). 
 Problem orientation.  Problem orientation is a schema (negative or positive) that 
influences how an individual copes with the everyday problems that he or she encounters 
(D’Zurilla & A. M. Nezu, 1990).  A. M. Nezu et al. (1989) explains that the cognitive-
affective-behavioral response guides the problem orientation and the problem-solving 
process.  The cognitive subcomponent of problem orientation is a set of fixed 
attributions, appraisals, and expectations about problems and problem-solving that tend to 
generalize across situations (D’Zurilla & A. M. Nezu, 1990).  The emotional (affective) 
state is the positive (e.g., hope) or negative (e.g., anger) feelings that are experienced in 
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reaction to the problem (D’Zurilla & A. M. Nezu, 1990).  How the individual chooses to 
respond to the problem (i.e., weigh pros and cons versus avoidance) is the behavioral 
subcomponent (D’Zurilla & A. M. Nezu, 1990).  These subcomponents of problem 
orientation dictate whether the person has a positive problem orientation (PPO) or a 
negative problem-solving orientation (NPO; Chang et al., 2004).  
PPO is a set of cognitive, affective, and behavioral skills that lend themselves to 
adaptive problem-solving abilities (Chang et al., 2004).  Those with a PPO tend to have 
the following characteristics: (a) the ability to appraise problems as a positive challenge; 
(b) the belief that problems can be solved, but that solving them may take time, effort and 
perseverance; and (c) the belief that they have the ability to solve problems and the 
willingness to invest in the problem-solving process (Chang et al., 2004).  Conversely, 
those with a negative problem orientation (NPO) tend to (a) see problems as a significant 
threat, (b) doubt their own ability to solve problems effectively, and (c) are easily 
discouraged when confronted with everyday problems (Chang et al., 2004).  
A. M. Nezu et al. (1999) looked at the role of SPS in women (N = 105) with 
newly diagnosed cancer (41% with breast cancer).  The results demonstrated the 
important role that adaptive (PPO) and maladaptive (NPO) problem-solving skills have in 
the management of cancer-related distress.  More specifically, patients with a NPO, 
reported higher rates of depression, anxiety, and cancer-related distress (A. M. Nezu, C. 
M. Nezu, Houts, Friedman, & Faddis, 1999).  Similarly, McClure et al. (2012) assessed 
problem-solving abilities, depression, and relationship satisfaction in 63 couples with one 
partner diagnosed with cancer.  The authors found that partners who viewed solving 
PROBLEM-SOLVING AND CANCER DECISIONS 20 
 
problems more positively were less likely to experience depression (McClure et al., 
2012). 
 Problem-solving styles.  Problem-solving styles are the cognitive and behavioral 
processes that determine which coping mechanisms are applied to problematic situations 
(D’Zurilla & A. M. Nezu, 1990).  Problem-solving styles include rational problem 
solving (RPS), impulsivity/carelessness style (ICS), and avoidance styles (AS; D’Zurilla 
& A. M. Nezu, 1990).  RPS is an adaptive problem-solving style that is defined as the 
deliberate and systematic application of effective problem-solving skills (D’Zurilla & A. 
M. Nezu, 1990).  Successfully applying RPS requires systematically collecting 
information about the problem, identifying obstacles, setting realistic goals, generating a 
list of alternative solutions, hypothesizing possible consequences of each solution, 
weighing the pros and cons of each of the alternatives and implementing the chosen 
solution, while also evaluating the outcome (D’Zurilla & A. M. Nezu, 1990).  
In contrast to the positive and proactive RPS style, ICS and AS problem-solving 
styles are considered dysfunctional.  To illustrate, compared to the systematic problem-
solving skills used in RPS, ICS is marked by impulsive choices, in which there is little 
thought put into how to go about solving the problem and the consequences that could 
result from the chosen solution.  In other words, the first solution that comes to mind is 
typically the solution that is implemented (D’Zurilla & A. M. Nezu, 1990).  Similarly, 
AS problem-solving includes avoidant behaviors, such as procrastination (D'Zurilla & A. 
M. Nezu, 1990).  These individuals avoid in the hopes that the problem will resolve on its 
own and, and when problems do not resolve, accountability is often placed on others 
(D’Zurilla & A. M. Nezu, 1990).  In sum, the consistent use of ICS and AS problem-
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solving sets results in an inability to cope when confronted with problems which, over 
time, lowers self-efficacy (D’Zurilla & A. M. Nezu, 1990; King et al., 2010). The 
relationship between consistently poor problem solving, lower self-efficacy and 
depression has been reported in both the diabetes self-management and suicidal risk 
literature (D’Zurilla, Chang, Nottingham, & Faccini, 1998; King et al., 2010).  In general, 
the ability to apply adaptive problem-skills is related to higher self-efficacy and 
optimism, which makes for improved coping and better adherence to treatment 
recommendations (D’Zurilla et al., 1998; King et al., 2010).  
 Problem-solving training.  The research on SPS and genetic testing decisions is 
limited.  Yet, there is literature to suggest that problem-solving training (PST) can 
decrease distress (Schwartz et al., 1998).  PST is a CB intervention that teaches people 
how to choose and carry out the most effective coping strategies (D’Zurilla, 1988). PST 
teaches patients how to proceed systematically through the problem-solving process and 
includes the following components: (a) defining the problem (i.e., obtain information 
about the problem, challenging cognitive distortions, set goals), (b) generate alternative 
solutions, (c) decision making, and (d) solution implementation and verification (A. M. 
Nezu, C. M. Nezu, Friedman, Faddis, & Houts, 1998).  
Nezu et al. (1998) argued that cancer is a secondary stressor that makes dealing 
with primary stressors (i.e., daily life events) much more stressful.  Additionally, poor 
premorbid problem-solving abilities increase the risk for cancer-related distress.  Thus, it 
is believed that improving SPS with PST can decrease general distress and cancer-related 
distress (A. M. Nezu et al., 1999).  Schwartz et al. (1998) demonstrated the effectiveness 
of PST in 144 women who had family histories of breast cancer.  The authors found that 
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women who received PST showed a significant decrease in cancer-related distress 
(Schwartz et al., 1998).  
Prophylactic Treatment  
The decision about whether to obtain genetic testing is complex due to the 
overlapping social, emotional, and biological consequences (Calzone & Biesecker, 2002).  
To decrease breast cancer risk, prophylactic treatment (e.g., mastectomy) is often 
recommended to high risk FDRs who have received positive genetic test results 
(Hartmann et al., 1999).  Nevertheless, the decision to undergo major life-changing 
surgery is not an easy one, especially for young women (Lerman et al., 2000).  There are 
numerous possible post-surgical outcomes that one may endure.  
Prophylactic treatments can include mastectomy (removal of either one or both of 
the breasts), oophorectomy (removal of the ovaries), chemoprevention (e.g., tamoxifen), 
or surveillance (e.g., frequent mammograms; Meijers-Heijboer et al., 2000).  Mastectomy 
is typically recommended in high risk cases, with bilateral mastectomy decreasing the 
risk of breast cancer by 95% (Rebbeck et al., 2004).  Although older research established 
a relationship between oophorectomy and decreased breast cancer risk in BRCA1 
mutation carriers, more recent research has negated this finding (Heemskerk-Gerritsen et 
al., 2015; Kotsopoulos et al., 2016; Rebbeck, Kauff, & Domchek, 2009).  In addition to 
or combined with surgical interventions, there are chemopreventive treatments such as 
tamoxifen, which is an estrogen blocker that aids in the prevention of breast cancer 
(Cuzick et al., 2015).  Although tamoxifen decreases breast cancer risk, it increases 
menopause-like symptoms and the risk for uterine cancer, which makes the treatment 
undesirable to many women (Cuzick et al., 2015).  
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 It is should not be surprising that weighing the pros and cons of preventative 
options can have a psychological impact.  When considering prophylactic treatments, 
level of cancer-related distress (i.e., anxiety; depression) can be exacerbated by younger 
age, past history of diagnosis, perceived risk, having young children, and a family history 
of cancer (Claes et al., 2005; Graves et al., 2012).  In addition, changes in fertility and 
body image are also significant components, as many of the women who are making 
these decisions are younger than age 35.  Conversely, there has been research that 
suggests that prophylactic surgery can decrease psychological morbidity due to the 
decrease in breast cancer risk (Brandberg et al., 2008).  In general, the influence that 
prophylactic treatment has on the genetic testing decision cannot be underestimated. 
Summary 
Genetic testing decisions are complex and uncertain.  The decision can be 
influenced by problem-solving abilities, health anxiety, and psychological distress.  
Previous exposure to a family member’s battle with breast cancer can further intensify 
and confound the decision (Dreer et al., 2009).  Other factors contributing to the decision-
making process are lack of resources (e.g., insurance, medical care, and education) and 
previous health behaviors (e.g., eating habits and adherence to medical recommendations; 
Lipscomb et al., 2012).  The implications of this study are twofold: First, the relationship 
between SPS, health anxiety, and psychological distress has yet to be evaluated in the 
context of BRCA1/BRCA2 genetic testing and prophylactic decisions.  Moreover, 
significant findings may suggest that the assessment of one’s SPS skills, health anxiety, 
and psychological distress should be incorporated into the pre- and post-genetic 
counseling sessions.  The ability to predict problem-solving skills post-genetic testing 
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may allow medical providers to address these issues from the beginning, thus helping the 
patients to feel empowered and to make decisions that are right for them.  Second, by 
examining SPS in relation to genetic testing, the hope was to provide a more concrete 
explanation for genetic testing and prophylactic treatment decisions, as the current body 
of literature is fairly small and inconsistent.  Thus, using hypothetical vignettes and a 
healthy sample, the aim of the current study was to determine how SPS, health anxiety, 
and psychological distress influence genetic testing and prophylactic decisions. 
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Chapter 3: Hypothesis 
This study explored the relationship between genetic testing decisions, SPS 
variables (i.e., problem-solving orientation, rational problem-solving style, avoidance and 
impulsivity/carelessness), psychological distress, and healthy anxiety.  This was 
examined by providing a healthy population with hypothetical vignettes about specific 
breast cancer scenarios. 
Hypothesis 
It was hypothesized that when provided with hypothetical vignettes in which a 
first degree relative has been found to have the BRCA1 and/or BRCA2 mutation, PPO, 
NPO, RPS, AS, ICS, levels of psychological distress, and/or health anxiety would predict 
the likelihood of whether women would elect to obtain genetic testing and/or 
prophylactic treatment. 
Rationale 
Individuals who utilize RPS are able to effectively and systematically define the 
problem, generate alternatives, evaluate alternatives, implement solutions, and then 
evaluate solutions.  These individuals were surmised to be more likely to feel less 
psychological distress than individuals who have less effective RPS skills.  Conversely, 
individuals with poor problem-solving abilities have a difficult time solving problems 
effectively and have a tendency to solve problems in an impulsive and careless style.  
Moreover, they also have a tendency to put off solving problems.  This type of 
dysfunctional problem-solving may lead to psychosocial distress.  Similarly, persons with 
high levels of health anxiety tend to make negative interpretations about health 
information, which can lead to increased anxiety.  In sum, regardless of decision, 
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participants who have a PPO and apply positive problem-solving skills are predicted to 
be more likely to agree to both genetic testing and prophylactic treatment.  
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Chapter 4: Method 
Research Design and Design Justification 
 In order to ensure the representativeness and generalizability of the sample, the 
study used a cross-sectional design.  The purpose of the current study was to examine the 
relationship between genetic testing and prophylactic decisions, SPS variables (i.e., 
problem-solving orientation, rational problem solving, avoidance and 
impulsivity/carelessness), psychological distress, and health anxiety.  The variables of 
interest were assessed by incorporating measures into an Internet survey format.  Web-
page-based surveys offer consistency, as they appear identical to all participants, have the 
ability to target a large demographic, and obtain data in a systematic fashion (Gray, 
Mann, & Stewart, 2001).  
Participants and Recruitment  
Due to the hypothetical nature of this study, the sample was drawn from a sample 
of healthy women (N = 130).  An effort was made to recruit a minimum of 102 
participants to reflect a .05 alpha and medium effect size (Cohen, 1992).  Participants 
were between the ages of 18 and 35.  The method of recruitment and study design 
required participants to have access to the Internet.  Efforts were made to recruit persons 
from diverse racial backgrounds.  
Inclusion criteria.  Participants considered for this study were healthy adult 
women with no prior or current diagnosis of breast cancer, no family history of breast 
cancer (in first or second-degree relatives), and/or had never tested positive for the 
BRCA1 or BRCA2 genetic mutation.  Eligible participants were between the ages of 18 
and 35, as research indicates that age is the biggest predictor in the decision to agree to 
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genetic testing, and that women over the age of 35 are generally more willing to obtain 
genetic testing (Alterkruse et al., 2010).  Participants were fluent in English and at a sixth 
grade reading level or higher, as determined by self-identification and the ability to 
comprehend the informed consent.  Participants of all races and ethnicities who met these 
stated criteria were included. 
Exclusion criteria.  Participants with a current or prior breast cancer diagnosis, 
the BRCA1 or BRCA2 genetic mutation, an FDR with a past or present history of cancer, 
and/or a second degree relative diagnosed with breast cancer were excluded from the 
study.  
Recruitment.   Recruitment for the study was done via ResearchMatch, a national 
health volunteer registry that was created by several academic institutions and supported 
by the U.S. National Institutes of Health as part of the Clinical Translational Science 
Award (CTSA) program.  ResearchMatch has a large population of volunteers who have 
consented to be contacted by researchers about health studies for which they may be 
eligible. 
Procedure   
Survey Monkey, an online resource used to create and administer surveys, was 
used to obtain the data.  Each survey included the informed consent, SPSI-R:S (D’Zurilla, 
Nezu, & Maydeu-Olivares, 2002), Short Health Anxiety Inventory (SHAI; Salkovskis, 
Rimes, Warwick, & Clark, 2002), Brief Symptom Inventory-18 (BSI-18; Derogatis, 
2001), and a demographics questionnaire.  The measures took approximately 30 minutes 
to complete.  After the survey was completed, participants were directed to a separate 
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survey, where they had the option to enter their e-mail addresses for a 1 in 10 chance to 
win a Target gift card.  The lottery drawing occurred after recruitment ended.  
Security.  Considerable steps were taken to ensure the protection of study 
participants.  Prior to the initiation of the study, the Institutional Review Board of the 
Philadelphia College of Osteopathic Medicine reviewed and approved the study.  
Recruitment for the study conducted through ResearchMatch and all study participants 
were recruited without coercion and were prompted to review the informed consent 
thoroughly before proceeding.  Participants were not identified by their names and all 
data were kept confidential with the use of a secure e-mail address.  
Measures 
 Clinical vignettes.  Hypothetical vignettes were presented to study participants as 
two distinct clinical scenarios, one addressing genetic testing decisions and the other 
addressing prophylactic decisions (Appendix).  Only those who indicated that they were 
willing to obtain genetic testing were evaluated on prophylactic decisions.  
Participants’ responses were scored on a Likert scale (extremely unlikely; unlikely; 
likely; extremely likely).  A neutral choice was not an option because in genetic testing 
and prophylactic decisions, a choice must be made; thus, choice was forced in these 
scenarios as well.  
 Social Problem-Solving Inventory-R:S (SPSI-R:S).  The SPSI-R:S is a widely 
utilized self-report measure that assesses everyday problem-solving abilities in five 
domains (D’Zurilla et al., 2002).  The SPSI-R:S assesses both problem orientation and 
problem-solving style.  Domains on the measure include, NPO, PPO, RPS, ICS and AS 
(D’Zurilla & A. M. Nezu, 1999; Yetter & Foutch, 2014).  The measure consists of 25 
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items with five scales and a total global score (Dreer et al., 2009).  Items are assessed on 
a 5-point Likert-type scale ranging from 0 (not at all true of me) to 4 (extremely true of 
me; Dreer et al., 2009).  The scales have a standardized mean of 100 and a standard 
deviation of 15.  Scores equal to or above 145 are considered to be extremely above norm 
group average and scores equal to or below 55 are considered to be extremely below 
norm group average (D’Zurilla et al., 2002).  The items on this measure have been found 
to have satisfactory predictive, convergent, structural, and discriminant validity 
(D’Zurilla et al., 2002).  The internal consistency ranges from .60 to .90 and the test-
retest reliability ranges from .68 to .91 (D’Zurilla et al., 2002).        
 Short Health Anxiety Inventory (SHAI).  The SHAI is an 18-item self-report 
questionnaire that measures normal health concern and more severe health anxiety 
(Salkovskis et al., 2002).  The SHAI includes four statements that ask about the level of 
health concerns over the past 6 months (Salkovskis et al., 2002).  Items are scored from 0 
to 3 and are added to obtain a main score, a negative consequences score. and a total 
score ranging from 0 to 54 (Alberts, Hadjistavropoulos, Jones, & Sharpe, 2013).  In the 
development of the SHAI, Salkovskis et al. (2002) reported norm scores among non-
psychiatric populations for illness anxiety (M = 9.4; SD = 5.1), negative consequences (M 
= 2.2, SD = 2.1), and total score (M = 12.2, SD = 6.2).  The authors also reported the 
health anxiety norm scores for the main section (M = 30.1, SD = 5.5), negative 
consequences (M = 7.8, SD = 2.8), and total score (M = 37.9, SD = 6.8; Salkovskis et al., 
2002).  Alberts et al. (2013) found that the internal consistency ranged from good to 
excellent (.74 to .96).  
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 Brief Symptom Inventory-18 (BSI-18).  The BSI-18 (Derogatis, 2001) is 
derived from the 53 item BSI (Derogatis & Spencer, 1993), and the SCL-90-R (Derogatis 
& Unger, 2010). The BSI-18 consists of three 6-item scales that measure both physical 
and emotional complaints on a 5-point Likert scale that measure psychological distress 
(Derogatis, 2001).  Raw scores are converted into T-scores, and a T-score greater or equal 
to 63 on any scale indicates a positive score for that scale.  Overall distress is determined 
by a T-score greater or equal to 63 on the Global Severity Index (GSI) or on two or more 
of the subscales.  The scales include somatization (SOMA), anxiety (ANX), depression 
(DEPR), and the GSI (Derogatis, 2001).  The BSI-18 has been found to be valid and 
reliable in patients with varying medical and mental illnesses (Carlson et al., 2004). 
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Chapter 5: Results 
Statistical Analysis 
A stepwise multiple regression was conducted to test the hypothesis that the SPS 
variables, health anxiety, and psychological distress would predict genetic testing and 
prophylactic decisions.  Relevant assumptions of the statistical analysis were tested.  The 
assumptions of singularity and collinearity statistics were tested and all independent 
variables were found to be sufficiently separate from each other (VIF = 1.00).  Personal 
information and predictor variables were analyzed with descriptive statistics (i.e., 
frequencies, means, standard deviations, and comparison), and Pearson product-moment 
correlations were conducted to identify possible relationships among variables. 
Demographic Information 
Descriptive statistics were calculated for all participants within the overall sample 
(N = 130) to summarize basic features of the data.  The mean age of the sample was 
28.42 (SD = 3.15).  Means and frequencies were used to describe the main characteristics 
of the sample (Table 3).  Any variable with missing data was replaced by using series 
means.  
 One hundred and twenty-four participants reported their age, with 68.48% of 
women being 27 or older (M = 28.42, SD = 3.15, age range: 18-35 years). Of the one 
hundred and thirty participants who responded to the question of marital status, 60 
reported being single, six engaged, 53 married, one divorced, zero widowed and 10 lives 
with a domestic partner. 130 participants responded about their education, including two 
with a high school diploma or GED, 9 with some college, six with an Associate’s Degree, 
54 with a Bachelor’s or four-year degree, 45 with a Master’s or other graduate degree and 
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14 with a doctorate or other professional degree. 130 answered about their employment 
status, with 94 participants employed for wages, three that were self-employed, two that 
were out of work but not currently looking for work, give that were homemakers and 26 
students.  
 
 
Table 3 
Participant Demographics 
 % N 
Marital Status    
   Single 46.15 60 
   Married 40.77 53 
   Divorced   0.77   1 
   Engaged   4.62   6 
   Living with a domestic     
   partner 
 
  7.69 10 
Education   
  High School Graduate or   
  GED 
   1.54   2 
  Some College    6.92   9 
  Associates Degree    4.62   6 
  Bachelor or 4-year degree 41.54 54 
  Masters or other graduate    
  Degree 
 
34.62 45 
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  Doctoral or other  
  professional degree 
10.77 14 
Employment Status   
  Employed for wages 72.31 94 
  Self-employed   2.31    3 
  Out of work but not  
  currently looking for   
  work 
  1.54   2 
  Homemaker   3.85    5 
  Student 20.00 26 
 
 
Health Behaviors  
The demographics questionnaire asked questions about specific health behaviors 
and diagnoses, including tobacco use, alcohol and drug use, past and current medical and 
psychiatric diagnoses, and compliance with medical appointments and recommendations 
(e.g., yearly physical, monthly self-breast exams, and gynecological appointments).  Out 
of the 130 participants who responded, 95.38% of participants denied tobacco use, 
76.92% responded “yes” to current alcohol use, and 34.62% admitted to using 
illicit/recreational drugs (current or past use was not indicated).  When asked about 
current medical diagnoses (N = 130), seasonal allergies (n = 6, 4.17%) and migraines (n 
= 6, 4.17%) were the most prevalent.  Anxiety (n = 41, 28.47%) and depression (n = 41, 
28.47%) were the most frequently reported psychiatric disorders among participants (N = 
130), followed by posttraumatic stress disorder (n = 7, 4.86%), bipolar disorder (n = 3, 
2.08%), and attention-deficit/hyperactivity disorder (n = 6, 4.17%).  The majority of 
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participants indicated that they receive annual check-ups from their primary care 
physicians (PCPs; n = 100, 69.44%) and OB-GYNs (ages 18-20: n = 25, 17.36%; ages 
21-29, n = 65, 45.14%; ages 30-35, n = 58, 40.28%).  In spite of these findings, more 
than half of the participants reported that they do not perform breast self-exams on a 
monthly basis (n = 100, 69.44%).  
Hypothetical Vignettes  
For Vignette 1 (Table 4), scores ranged from 1 to 5 (M = 4.33, SD = 0.96).  More 
than half (51%; n = 77) reported that they would be “extremely likely” to obtain genetic 
testing, 36.11% (n = 52) said they “likely” would, 8.33% (n = 12) said it would be 
“unlikely” for them to receive testing, and 2.08% (n = 3) said it would be “extremely 
unlikely.”  For Vignette 2 (Table 5), participants who answered “likely” or “extremely 
likely” in Vignette 1 were asked to respond to a second vignette that addressed whether 
they would be open to receiving prophylactic treatment (i.e., mastectomy) if they were 
found to have the BRCA1 or BRCA2 genetic mutation.  One hundred twenty-nine 
participants responded (range = 1-4; M = 2.76, SD = 0.82).  Fifty-eight participants 
(38.40%) reported that they would be “likely,” 39 (25.80%) said “unlikely,” 24 (15.90%) 
said “extremely likely,” and 8 (5.30%) said “extremely unlikely.”   
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Table 4 
Vignette 1: Descriptive Statistics Table 
 % n 
Extremely Unlikely   2.0   3 
Unlikely   7.9 12 
Likely 34.4 52 
Extremely Likely 51.0 77 
 
 
Table 5 
Vignette 2: Descriptive Statistics Table 
 % N 
Extremely Unlikely   5.3   8 
Unlikely 25.8 39 
Likely 38.4 58 
Extremely Likely 24.0 15.9 
 
 
 
Social Problem-Solving 
The mean score on the SPSI-R:S (Table 6) was 106.39 (SD = 13.21; range: 62-
135; 63 = very much below norm group average; 135 = above norm group average).  The 
majority of participants (N = 137) fell within the norm group average.  Having average 
problem-solving skills increases the likelihood that one will be able to cope effectively 
and experience less psychological distress when negotiating stressful situations. 
Table 6 
Social Problem-Solving Inventory-Revised, Short Form Descriptive Statistics 
Subscale N Minimum Maximum Mean Standard 
Deviation 
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Positive 
Problem 
Orientation 
137 62 131 98.94 16.61 
 
Negative 
Problem 
Orientation 
 
137 
 
74 
 
135 
 
94.10 
 
12.09 
 
Rational 
Problem 
Solving 
 
137 
 
64 
 
136 
 
98.74 
 
16.05 
 
Impulsivity/
Carelessness 
Style 
 
137 
 
73 
 
134 
 
92.36 
 
11.34 
 
Avoidance 
Style 
 
137 
 
78 
 
125 
 
86.97 
 
11.57 
 
SPSIRS 
Total Score 
 
137 
 
63 
 
135 
 
106.39 
 
13.21 
  
 
Health Anxiety  
The SHAI (range: 0-54) has two distinct components.  The first assesses the 
person’s perceived likelihood that he or she will become ill (illness likelihood [IL]) and 
the second assesses the perceived consequences of having the illness (negative 
consequences of illness [NC]). The mean scores (N = 137; total SHAI: M = 29.37, SD = 
5.63) of the components were IL (M = 29.37, SD = 5.14) and NC (M = 4.97, SD = 1.39).  
Table 7 illustrates results of the SHAI. 
 
Table 7 
Short Health Anxiety Inventory Descriptive Statistics 
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Subscale N Minimum Maximum Mean Standard 
Deviation 
Illness 
Likelihood 
(IL) 
 
140 15 46 24.40 5.14 
Negative 
Consequence 
of Illness 
(NC) 
 
 
140 
 
3 
 
10 
 
4.97 
 
1.39 
Total Score 140 19 53 29.37 5.63 
  
 
Psychological Distress 
The BSI-18 was used assess current psychological distress over the past 7 days.  
In addition to the GSI (max raw score = 72), separate scores were calculated on three 
subscales: SOM, DEP, and ANX, with six questions contributing to each subscale (max 
raw score = 24).  The mean scores on all subscales and the GSI showed increased levels 
of psychological distress.  Table 8 displays results of the BSI-18.   
 
Table 8 
Brief Symptom Inventory-18 (Scaled Scores) Descriptive Statistics 
Subscale N Minimum Maximum Mean Standard 
Deviation 
Somatization 137 41                  69 48.24 7.33 
Depression  137                  40                   74              48.91 8.50 
Anxiety  137                  38                  81 49.21 9.01 
Global 
Scaled Score 
               137                  33                     75 48.60 8.57 
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Stepwise Regression Analysis: Vignette 2 
A multiple stepwise regression was completed to determine the best linear 
combination of scores on the SPSI-R:S, SHAI, and BSI-18 for predicting 
BRCA1/BRCA2 genetic testing decisions in hypothetical FDRs.  It was hypothesized that 
the three measures as well as problem-solving orientation and styles on the SPSI-R:S 
(PPO, NPO, RPS, ICS, and AS) would predict the decision of whether to receive genetic 
testing (Vignette 1) and, if yes, prophylactic treatment.  PPO significantly predicted 
prophylactic treatment decisions, F(1,121) = 3.97, p = .05.  The adjusted R squared 
equaled .024, meaning that 2.4% of the variance in prophylactic treatment decisions can 
be predicted from PPO.  Tables 9 through 13 depict the stepwise regression analysis.  
 
 
Table 9 
Stepwise Regression Model Summary 
Model Variable R  R Square Adjusted R 
Square 
Std. Error of 
the Estimate 
1 PPO .178 .032 .024 .82064 
 
 
Table 10 
Stepwise Regression Model Summary, Change Statistics 
Model Variable R Square 
Change 
F Change Df1 Df2 Sig. F 
Change 
1 PPO .032 3.971 1 121 .049 
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Table 11 
Stepwise Regression Model Summary, Excluded Variables 
Model Variable Beta In T Sig. Partial 
Correlation 
Collinearity 
Statistics: 
Tolerance 
1 NPO  .016 .153 .879 .014 .723 
 
 RPS .108 .954 .342 .087 .620 
 
 ICS .020 .218 .828 .020 1.00 
 
 AS -.030 -.307 .760 -.028 .854 
 
 BSI Global 
Score 
 
.084 .913 .363 .083 .957 
 HAI Total 
Score 
.094 1.02 .309 .093 .948 
 
Table 12 
ANOVA 
Model  Sum of 
Squares 
Df Mean 
Square 
F Sig.  
1 Regression 2.674 1 2.674 3.971 .049 
 Residual 81.488 121 .673   
 Total  84.163 122    
 
Table 13 
Collinearity Coefficients 
Model  Unstandardized 
Coefficients 
B 
Unstandardized 
Coefficient 
Std. Error 
Standardized 
Coefficient 
B 
   t Sig.  
1  
Constant 
 1.88 .447 2.674 3.9 
 
.049 
    PPO     
    
Standard  
    Score 
  
 
.009 
 
 
.004               
 
 
.673                 
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Chapter 6: Discussion  
Demographic Variables 
 In the current study, 51% of participants indicated that they would be “extremely 
likely” to receive genetic testing.  This is less than what has been reported in prior 
research using hypothetical samples.  As previously discussed, Ropka et al. (2006) 
completed a systematic review of breast cancer genetic testing uptake rates in both 
hypothetical and real scenarios.  The authors determined that participants in hypothetical 
situations were more amenable to testing than participants in real situations (mean 
hypothetical genetic testing uptake rate = 66%; mean real genetic testing uptake rate = 
59%).  Indeed, the uptake rates reported in hypothetical and real breast cancer genetic 
testing research are variable (range = 20% to 96%; Ropka et al., 2006).  The reasons for 
this variability are likely due to differences in study methodology, sampling strategy (i.e., 
reference versus convenience), recruitment setting, personal history of breast cancer, 
and/or family history of breast cancer (Ropka et al., 2006).  To illustrate, most studies 
differ in how they operationally define and measure interest in genetic testing versus 
intent to obtain genetic testing (Glanz, Grove, Lerman, Gotay, & Le Marchand, 1999).  
Accordingly, the discrepancies in genetic testing uptake are partly attributable to a body 
of research that has been unsystematic in its methodology (Bowen, Patenaude, & Vernon, 
1999).   
The current study faced some of the same issues as other research completed in 
this area (e.g., homogenous sample; hypothetical, non-patient sample; convenience 
sampling).  As stated previously, the hypothetical nature and the homogeneity of the 
sample have limited the representativeness and generalizability of the study findings to 
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the national FDR BRCA1/BRCA2 demographic.  The overall mean age for this sample 
was 28.42 years, with the majority of participants being between the ages of 27 and 35.  
The mean age of women who responded that they would be “extremely likely” or 
“likely” to receive genetic testing was 28.50 years.  The mean age of women who 
reported that they would be “extremely likely” or “likely” to obtain prophylactic 
treatment (i.e., mastectomy) was 29 years.  The study only included women in the 18 to 
35 age range because there is research suggesting genetic testing decisions in this age 
range are uniquely complex because of this particular stage of development (i.e., 
achieving independence from their parents), the reproductive and physical repercussions 
of having breast cancer (i.e., childbearing, changes in sexual functioning and body 
image), and the national guidelines in the U.S. (Evans et al., 2016; Patenaude et al., 
2013).     
Considering that the genetic testing research on young women FDRs is sparse, the 
current study made the decision to incorporate women between the ages of 18 and 35 to 
gain a better sense of the determinants of their possible distress, health anxiety, and 
problem-solving processes.  It is unclear whether the uptake rates reported in this study 
are representative for several reasons: (a) this study was hypothetical and, because of this, 
the sample cannot be generalized to women in real genetic testing situations and (b) even 
though younger age is a predictor of willingness to obtain genetic testing, it may have 
been helpful to include women over the age of 35.  Seeing that this study was 
hypothetical, that genetic testing uptake rates reported in the literature are variable, and 
that little research has been done in young women in this area, it is unclear whether the 
uptake rates reported in this study are representative.  
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Women were also asked about their marital statuses, education levels, 
employment statuses/types of employment, health information (i.e., medical/mental 
health histories), health behaviors (i.e., engagement of monthly breast exams), and uptake 
of yearly physicals and gynecological exams.  The majority of women in this study had a 
bachelor’s degree or higher and worked in healthcare professions.  Nearly all of the 
womenvi reported that they visit their PCPs for yearly physicals (69.44%); however, 
women do not visit the OB-GYN as frequently for their yearly or biennial appointments 
(ages 18-20: 17.36%; ages 21-29: 45.14%; ages 30-35: 40.28%).  Correspondingly, 
69.44% of women indicated that they do not give themselves monthly breast self-exams 
(BSE).  The American Cancer Society updated the breast cancer screening guidelines, 
stating that monthly BSE is no longer necessary (Oeffinger et al., 2015).  Nevertheless, 
BSE is still strongly recommended in women who are at a higher risk of developing 
breast cancer (NCCN, 2018).  Therefore, although the study was hypothetical, the 
decision was made to assess for BSE in the present study.  In regard to psychiatric illness, 
more than half the women (56.25%) in this sample reported the absence of any current or 
prior psychiatric disorders.  Depression and anxiety occurred in 28.47% of the women 
but did not predict either the decision to obtain genetic testing or to seek prophylactic 
treatment. 
None of the demographic variables were found to be significantly predictive of 
genetic testing and/or prophylactic decisions.  The sample used in this study was 
homogeneous and represented a group of women who worked primarily in healthcare and 
who were more highly educated than women in the average population, which could 
account for the lack of significant findings.  Nonetheless, these findings are consistent 
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with other research that has shown education level, marital status, and psychological 
distress to be poorly predictive of genetic testing and prophylactic treatment decisions 
(Bellcross et al., 2015; Meiser et al., 2000; Schwartz et al., 2002).  A prior diagnosis of 
cancer, family history of cancer (particularly in a mother or sibling), levels of cancer-
related distress, and degree of perceived risk are considered to be most predictive of 
genetic testing uptake (Bellcross et al., 2015; Meiser et al., 2000; Metcalfe et al., 2008).  
The fact that women in the current study reported low attendance to OB-GYN 
appointments was somewhat unexpected.  Yet, there is data to suggest that people who 
have less education and are of lower SES visit their PCPs more frequently than those who 
are of higher SES (Dunlop, Coyte, & McIsaac, 2000).  Conversely, higher SES 
individuals tend visit PCPs less but are more likely to be given referrals and attend 
appointments with specialists (Dunlop et al., 2000).  The present findings may have 
implications for genetic testing and prophylactic treatment access in women from low 
SES backgrounds.  For instance, cost, logistical barriers, lack of support, and 
psychological distress have all been identified as important factors for not following up 
with genetic testing and are often issues that women from low SES backgrounds face 
(Willis et al., 2017).  Thus, to ensure that these obstacles do not hinder medical access to 
specialists, it is important for medical providers to identify barriers to treatment early on.  
Moreover, for the purposes of the current study, findings that higher SES populations are 
less likely to visit their PCPs may explain the low uptake of medical visits that were 
reported (i.e., the sample was more highly educated and may have come from higher SES 
backgrounds).  
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Psychological Distress, Health Anxiety, and Social Problem-Solving 
The goal of this study was to determine whether SPS variables (i.e., problem-
solving orientation, rational problem solving, avoidance, and impulsivity/carelessness), 
psychological distress, and healthy anxiety predict genetic testing and prophylactic 
treatment decisions in a hypothetical, non-patient sample.  Assessment of these variables 
was completed via a one-time survey in which participants were asked to complete three 
questionnaires and respond to two hypothetical vignettes.  
Results from this cross-sectional study revealed that mean scores fell within the 
normal range on the BSI-18, SHAI, and SPSI-R:S (domains PPO, NPO, RPS, ICS, and 
AS).  In other words, women in this study did not demonstrate significant levels of 
psychological distress or health anxiety and fell in the normal range for problem-solving 
orientation and ability.  With the exception of PPO, none of the questionnaires were 
significantly predictive of willingness to obtain genetic testing or prophylactic treatments.  
Specifically, scores on the BSI-18 ranged from low distress to clinically 
significant distress, but clinical significance was not reached for any of the scales.  
Likewise, SHAI scores were broad and ranged from extremely low to extremely high.  
Subscale scores were higher than those in average non-psychiatric populations; however, 
psychological distress was not found to be predictive of genetic testing or prophylactic 
treatment decisions.  These findings are consistent with prior research in which levels of 
cancer-related distress and state-trait anxiety were measured after receiving genetic 
testing.  The psychological distress level of non-carriers returned to normal range pre- to 
posttest and general levels of distress remained stable (Claes et al., 2005). 
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Women’s scores on the SPSI-R:S fell within the average range.  In all domains, 
scores on this measure ranged from below the norm group average to above the norm 
group average.  Neither problem orientation nor problem-solving style was found to be 
significantly predictive of genetic testing decisions.  In regard to prophylactic decisions, 
four out of the five domains (NPO, RPS, ICS, & AS) and the total score failed to predict 
any variance in prophylactic treatment choice.  In contrast, PPO was found to 
significantly predict prophylactic treatment decisions (i.e., mastectomy).  
It is worth mentioning that having children can influence genetic and prophylactic 
treatment decisions, even in hypothetical populations (Meijers-Heijboer et al., 2000).  
Regrettably, the present study did not ask participants if they had children and the 
opportunity was missed to evaluate this variable; however, three women in the study 
(between the ages of 30 and 35) indicated they were currently pregnant.  In healthy 
women, it is widely recognized that carrying more than one baby to full-term reduces 
breast cancer risk (Lecarpentier et al., 2012).  Conversely, there is research to suggest that 
increased estrogen production in pregnancy increases breast cancer risk in BRCA1 
mutation carriers (Andrieu et al., 2006; Antoniou et al., 2006; Lecarpentier et al., 2012; 
Milne et al., 2010).  The research on the risk of pregnancy and breast cancer in BRCA2 
mutations is inconclusive (Friebel et al., 2014).   
Of the three pregnant women, two responded that they would be willing to receive 
both genetic testing and prophylactic treatment.  The third participant was agreeable to 
genetic testing but stated that she would not accept prophylactic treatment.  The women 
did not endorse significant symptoms of psychological distress or health anxiety.  
Interestingly, the participants who were agreeable to both vignettes yielded RPS scores 
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on the SPSI-R:S that were below norm average (i.e., these women may have below 
average problem-solving abilities).  Although these findings are not meant to indicate 
significance, the data emphasize the complicated decisions that premenopausal women 
are confronted with when making these types of decisions.  
The implications of the current findings are important because PPO has been 
found to facilitate psychological distress reduction.  McInerney-Leo et al. (2004) assessed 
psychological well-being in 212 individuals from HBOC families.  Regardless of genetic 
testing decision (85% were agreeable), participants were randomized to receive either 
PST or client-centered counseling.  Those who received PST experienced a significant 
decrease in distress compared to those who received client-centered counseling 
(McInerney-Leo et al., 2004).  Thus, regardless of decision choice, a PPO during real-life 
genetic testing may increase confidence in the ability to make decisions, despite the 
outcome.  These results should to be interpreted with caution, as the amount of variance 
that predicted prophylactic treatment decisions was small (2.4%), and it is possible that 
other variables in the study impacted how the question was answered (e.g., education 
level, age). 
It is not surprising that this study did not generate significant levels of 
psychological distress or health anxiety but did show a relationship between PPO and 
treatment decisions.  In the literature, individuals with a PPO typically present with 
decreased levels of distress and generalized problem-solving self-efficacy (i.e., the belief 
that one is capable of solving problems and carrying out solutions effectively; Nezu, 
2004).  For example, research shows that being able to assert more control over chronic 
pain leads to a decrease in functional impairment (Shaw, Feuerstein, Haufler, Berkowitz 
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& Lopez, 2001; Suso-Ribera, Camacho-Guerrero, McCracken, Maydeu-Olivares, & 
Gallardo-Pujol, 2016). 
The pain literature regarding self-management and control demonstrates the value 
of self-efficacy (Lackner, Carosella, & Feuerstein, 1996).  For example, functional self-
efficacy expectancy—the view that an individual has the ability to complete work tasks 
effectively—is a better predictor of adaptive coping than psychological distress or 
perceived pain control (Lackner et al., 1996).  The mechanism underlying the relationship 
between positive problem-solving and increased self-efficacy is thought to be the result 
of operant learning (Shaw et al., 2001).  Put another way, how a person responds to 
problems in his or her daily life will generate behavioral responses, some of which will 
be reinforced and some of which that will not be (e.g., less distress in response to genetic 
testing or prophylactic decisions acts as negative reinforcement; Shaw et al., 2001).  
Thus, regardless of the decision, the ability to successfully implement effective problem-
solving skills in the context of genetic testing and prophylaxis may be a protective factor 
against the onset of psychological morbidity.  
Implication of the Research Findings 
Findings of the present study show that in hypothetical samples, levels of 
psychological distress, health anxiety, and problem-solving ability are not predictive of 
BRCA1/BRCA2 genetic testing decisions.  In contrast, PPO is predictive of prophylactic 
treatment decisions (i.e., mastectomy), whereas the other study variables are not.  This 
study is novel in that it is the first to show a specific relationship between problem-
solving orientation, BRCA1/BRCA2 mutation status, and prophylactic treatment 
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decisions.  This finding advances the idea that positive problem-solving abilities aide in 
the decision-making process in high risk HBOC families (Caplan, 1981; Pasacreta, 1999).  
Research in genetic testing decisions in individuals at risk for the Huntington’s 
disease genetic mutation has demonstrated similar findings.  Perceived risk, although 
important, was found to be secondary to one’s personality profile and coping mechanisms 
(Decruyenaere et al., 1996).  Similarly, a follow-up study found that individuals who 
chose to obtain genetic testing were more likely to employ active problem-solving skills, 
report a higher frequency of optimistic thoughts, and seek support more often (Evers-
Kiebooms, Welkenhuysen, Claes, Decruyenaere & Denayer, 2000).  Nevertheless, since 
this study did not find problem-solving orientation or style to be significantly predictive 
of genetic testing decisions and research on SPS in prophylactic decisions is limited, it 
remains unclear at this time whether findings of that nature can be applied to the current 
study.  Moreover, though the findings from this study are intriguing, there continues to be 
a lack of consensus as to what providers should be addressing with patients (e.g., 
premorbid psychiatric illness, cancer related psychological distress versus perceived 
risk).  Although hypothetical, the current findings add to a growing body of research 
suggesting that assessment of psychological variables and coping mechanisms should be 
integrated into the initial genetic counseling session (Koch & Svendsen, 2005.  
   To emphasize the importance of considering SPS within the domain of 
prophylactic decisions, Koch and Svendsen (2005) hypothesized that cancer genetic 
testing is inherently non-directive and that effective genetic counseling provides 
direction, thus increasing one’s sense of autonomy and informed consent.  Therefore, the 
genetic counselor’s task is to ensure that the patient feels fully informed about all aspects 
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of the genetic testing process (e.g., risk, the treatment consequences of receiving a 
positive result).  The nature of BRCA1/BRCA2 genetic testing is to present prophylaxis 
as the solution the problem of the possibility of being positive for the mutation.  Thus, 
patients engage in a process in which their problems are viewed in the context of the 
available solutions, which can increase optimism and self-efficacy and protect against 
psychological distress and health anxiety (Casey & Edgerton, 2008; Spector & Kitsuse, 
2001). 
 It makes sense that a solution-focused strategy combined with feelings of 
autonomy may lead to increased optimism and self-efficacy, thus making the problem-
solving and decision-making processes empowering versus distressing.  Further, patients 
who have a stronger sense of self-efficacy, internal sense of control, and optimism may 
choose prophylactic approaches, which are consistent with an active rather than passive 
approach to problem-solving.  The findings of past research and the current study 
highlight that providers involved in the dissemination of information on genetic risk 
should be take the time to ensure that patients have understood the information that has 
been provided to them adequately.  With this in mind, successfully navigating genetic 
and prophylactic treatment decisions means acquiring information that may lead to or 
exacerbate psychological distress and health anxiety.  Even though this study did not find 
a predictive relationship between psychological variables and genetic testing or 
prophylactic decisions, it revealed evidence that problem-solving ability is asserting some 
influence on the decision-making process.  Thus, problem-solving ability may need to be 
considered when asking women at risk for breast cancer to make complex decisions 
about their future health.  
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Limitations of Current Study 
Similar to other studies in HBOC domain, the sample used in the current study 
was fairly homogeneous, particularly in regard to education and profession, and may not 
generalize to the entire population.  It is important to note that due to human error, 
information on race and ethnicity was not collected; however, pending IRB approval, 
study subjects will be contacted and asked to fill out race and ethnicity information in a 
separate survey.  In addition, groups were not balanced by age, which led to a large 
proportion of study participants being older than 27.  
Another limitation of this study was the use of hypothetical vignettes versus a real 
sample of women undergoing genetic testing and/or prophylactic treatment decisions.  
According to the diathesis-stress model, a life stressor such as cancer could trigger the 
onset of psychiatric illness (Vitaliano et al., 1998; Zubin & Spring, 1977).  Thus, since 
the study participants were not actually in the situation of being genetically tested or 
having to decide whether to get a mastectomy, no stress was triggered and, consequently, 
they were less likely to experience psychological distress or health anxiety.  These issues 
may limit the external validity, thus impacting the generalizability of the study.  
In terms of other variables, the younger age of this cohort may have impacted 
level of breast cancer knowledge as well as the overwhelming willingness to receive both 
genetic testing and prophylactic treatment.  Over the course of their lifetimes, this group 
of women had more access to health literacy via school and/or technology (e.g., the 
Internet) than generations in the past.  Access to these resources may have increased the 
awareness of breast cancer risk, breast cancer screening, available breast cancer 
treatments, and the consequence of not following screening guidelines.  For example, 
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through the use of a text messaging intervention, a recent study demonstrated a 
significant increase in cervical cancer screenings (Lee, Koopmeiners, Rhee, Raveis, & 
Ahluwalia, 2014).  This research highlights how technology has changed the ways in 
which young people in today’s societies gather information to make informed medical 
decisions.  Finally, this study failed to consider women of Ashkenazi Jewish descent, 
who are at a higher risk for breast cancer.  
Future Directions  
The impact of genetic testing and prophylactic decisions on psychological 
functioning should not be minimized.  Despite the limitations of this study, it was one of 
the first to demonstrate that SPS, specifically PPO, is predictive of BRCA1/BRCA2 
prophylactic treatment decisions.  Future research should look at these relationships in 
larger non-hypothetical samples and in different disease groups to determine whether the 
results differ.  More specifically, BRCA1/BRCA2 mutations are also responsible for 
other cancers, most notably ovarian cancer; therefore, the next step may be to assess the 
study variables in the context of ovarian cancer.  
In addition, considering that SPS has been found to be quite successful in 
decreasing psychological distress, it stands to reason that incorporating problem-solving 
measures and problem-solving therapy into pre- and post-genetic counseling sessions 
may alleviate short and/or long-term distress (McInerney-Leo et al., 2004).  Accordingly, 
developing a more comprehensive understanding of the ways in which SPS, health 
anxiety, and psychological distress impact genetic testing and prophylactic decisions may 
provide valuable insight into how to better assist patients and their families and medical 
providers.  Nevertheless, as previously discussed, the majority of research in this area 
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either has methodological issues or is sparse, which may be why there continues to be 
disagreement in the literature.  If possible, efforts should be made to standardize 
treatment protocols (i.e., through the development of randomized control trials) and to 
incorporate heterogeneous samples.  Finally, further investigation of SPS, psychological 
distress, and health anxiety in BRCA1/BRCA2 genetic mutations among different races, 
ethnic groups, and genders is warranted.  
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Appendix 
Clinical Vignettes 
1. You have a family history of Breast Cancer in one of your first-degree relatives (mom 
or sister). You recently found out that your mother is a carrier of the breast cancer 
gene. You discuss your concerns with your OB-GYN who suggests that you see a 
genetic specialist for further testing. The testing will determine if you carry certain 
genes that increase your chances of getting breast cancer. What is the likelihood that 
you would receive the genetic testing? 
2. In the previous question you indicated you would be “Likely” or “Extremely Likely” 
to obtain genetic testing. Please read the information below and consider the 
following scenario: Based on the situation described, if you were found to have the 
BRCA1 or BRCA2 gene would you elect to have your breasts surgically removed to 
decrease your chances of getting breast cancer? Breast removal reduces the chance of 
getting breast cancer by 90-95%. 
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Endnotes 
1
SEER (Surveillance, Epidemiology, and End Results Program) 9 Registry: Contains epidemiological 
information from 1973 and later for Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-
Oakland, and Utah. Seattle-Puget Sound and Atlanta joined Seer in 1974. 
 
2SEER 13 Registry: Contains all information included in Seer 9 Registry as well as Los Angeles, San   
Jose-Monterey, Rural Georgia and the Alaska Native Tumor Registry. Data from 1992 and later is included 
for these registries. These registries report on expanded race. 
 
3 Number of New Cases and Deaths Per 100,000 People (All Races, Males and Females), Age-Adjusted 
    
  
 
 
4
Patients had a family history of breast, ovarian or colon cancer. 
5
Note: Groups were unbalanced, Age: 18-20: 3 subjects; 21-29: 80 subjects; 30-35: 5 subjects   
                                                 
